Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCVJK9)

Drug Name
PMID19788238C66 Drug Info
Synonyms 1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44478401
TTD Drug ID
DMCVJK9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Ephrin type-B receptor 1 (EPHB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-A receptor 5 (EPHA5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-A receptor 3 (EPHA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ifabotuzumab DMGWNCJ Acute myeloid leukaemia 2A60 Phase 2 [3]
KB-004 DM5U3IF Haematological malignancy 2B33.Y Phase 1/2 [4]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
PMID21561767C8h DMABZH6 Discovery agent N.A. Investigative [5]
Drug(s) Targeting Ephrin type-A receptor 1 (EPHA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-B receptor 4 (EPHB4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [6]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
TG-100435 DMIR3X2 Discovery agent N.A. Investigative [7]
EphB4-131 DM3F427 Solid tumour/cancer 2A00-2F9Z Investigative [8]
Drug(s) Targeting Ephrin type-B receptor 3 (EPHB3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-A receptor 7 (EPHA7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
PMID21561767C8h DMABZH6 Discovery agent N.A. Investigative [5]
Drug(s) Targeting Ephrin type-A receptor 2 (EPHA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CAR-T cells targeting EphA2 DMN3C2I Malignant glioma 2A00.0 Phase 1/2 [9]
BT5528 DMYBKMV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
DS-8895 DM31VNC Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
MEDI-547 DM3WP70 Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
MEDI-543 DM7Q1PF Solid tumour/cancer 2A00-2F9Z Preclinical [13]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [14]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
PMID21561767C8h DMABZH6 Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting Ephrin type-A receptor 8 (EPHA8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-A receptor 4 (EPHA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI-542 DM4G0D5 Solid tumour/cancer 2A00-2F9Z Terminated [15]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
Drug(s) Targeting Ephrin type-B receptor 2 (EPHB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [16]
SEphB4-HSA DMD8RU0 Kaposi sarcoma 2B57 Phase 2 [17]
KO-947 DMZMSBI Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
MK-8353 DMLCTI5 Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [14]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [2]
SNEWIQPRLPQH DMYUH62 Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ephrin type-A receptor 1 (EPHA1) TTLFZVU EPHA1_HUMAN Inhibitor [1]
Ephrin type-A receptor 2 (EPHA2) TTRJB2G EPHA2_HUMAN Inhibitor [1]
Ephrin type-A receptor 3 (EPHA3) TTHS2LR EPHA3_HUMAN Inhibitor [1]
Ephrin type-A receptor 4 (EPHA4) TTG84D3 EPHA4_HUMAN Inhibitor [1]
Ephrin type-A receptor 5 (EPHA5) TTV9KOD EPHA5_HUMAN Inhibitor [1]
Ephrin type-A receptor 7 (EPHA7) TTAHTVG EPHA7_HUMAN Inhibitor [1]
Ephrin type-A receptor 8 (EPHA8) TTHZ2LW EPHA8_HUMAN Inhibitor [1]
Ephrin type-B receptor 1 (EPHB1) TT8MDAC EPHB1_HUMAN Inhibitor [1]
Ephrin type-B receptor 2 (EPHB2) TTKPV6O EPHB2_HUMAN Inhibitor [1]
Ephrin type-B receptor 3 (EPHB3) TT5LM7U EPHB3_HUMAN Inhibitor [1]
Ephrin type-B receptor 4 (EPHB4) TTI4ZX2 EPHB4_HUMAN Inhibitor [1]

References

1 Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
2 Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Kalobios.
5 Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
6 XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26.
7 Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1833).
9 ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
10 MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
11 Clinical pipeline report, company report or official report of Daiichi Sankyo.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
13 Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
14 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15 Product Pipeline Review of MedImmune, LLC in 2012.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
18 Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.